Grifols A : Capital Markets Day 2021: innovation as the next growth pillar
>+10%-20% plasma supply expected for 2021 (vs. 30% previous guidance and our +26% estimate) but with a higher number of centers by YE - Grifols has revised downwards the levels of plasma supply for 2021 due to a slower recovery as the US government's stimulus packages for lower income citizens have reduced the donor flows in 1Q21. Grifols expects to close 2021 with 380 plasma centers growing to 520 in 2026, above our estimates of 374 and 438, respectively. We were exp...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.